REG - Alliance Pharma PLC - Exercise of Options <ALAPH.L>
.
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100504:nRSD2667La
RNS Number : 2667L
Alliance Pharma PLC
04 May 2010
For immediate release 4 May 2010
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Exercise of Share Options
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that on 4 May 2010 it allotted 49,150
ordinary shares of 1 pence each in the company ("Ordinary Shares") in satisfaction of employee share option exercises.
Application has been made for the 49,150 Ordinary Shares to be admitted to AIM, and trading is expected to commence on
10
May 2010 ("Admission"). Upon Admission, these shares will rank pari passu in all respects with the existing Ordinary
Shares of the Company.
After Admission, Alliance will have 228,008,676 Ordinary Shares in issue.
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
John Dawson, Chief Executive
Richard Wright, Finance Director
www.alliancepharma.co.uk
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic / Jennie Spivey
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Brent Nabbs
Corporate Broking: David Poutney
Corporate Broking: David Poutney
Notes to editors:
About Alliance
Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The
Company has a strong track record of acquiring the rights to established niche products and, following the Cambridge
Laboratories acquisition, owns or licenses the rights to more than 50 pharmaceutical products and continues to explore
opportunities to expand the range.
Alliance's products are prescribed in the treatment of a wide range of conditions and include products used in the
treatment of dermatological conditions, in oncology, in childbirth, in the prevention of heart disease, in Parkinson's
disease, in nutrition and in nasal infections. Alliance's sales are mainly prescription driven. Its products are
distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies
with
their prescription requirements.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS
The company news service from the London Stock Exchange
